Barclays PLC Acquires 71,730 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Barclays PLC lifted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 346.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,444 shares of the company’s stock after purchasing an additional 71,730 shares during the quarter. Barclays PLC’s holdings in Prestige Consumer Healthcare were worth $6,665,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PBH. Ariel Investments LLC lifted its position in Prestige Consumer Healthcare by 10.7% during the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after buying an additional 274,212 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after acquiring an additional 171,357 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Prestige Consumer Healthcare by 19.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after purchasing an additional 255,045 shares during the last quarter. Congress Asset Management Co. grew its stake in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after purchasing an additional 62,411 shares in the last quarter. Finally, Boston Trust Walden Corp acquired a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $41,785,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $78.79 on Thursday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.95 and a fifty-two week high of $86.36. The firm has a market capitalization of $3.89 billion, a PE ratio of 19.17, a PEG ratio of 2.32 and a beta of 0.49. The company’s 50-day moving average is $78.86 and its 200-day moving average is $72.90. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.07 earnings per share. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last quarter. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.